Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Q3 2025 value amounting to 1.96%.

  • Mirum Pharmaceuticals' EBITDA Margin rose 159900.0% to 1.96% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.86%, marking a year-over-year increase of 224000.0%. This contributed to the annual value of 26.0% for FY2024, which is 325600.0% up from last year.
  • According to the latest figures from Q3 2025, Mirum Pharmaceuticals' EBITDA Margin is 1.96%, which was up 159900.0% from 3.9% recorded in Q2 2025.
  • Mirum Pharmaceuticals' EBITDA Margin's 5-year high stood at 1.96% during Q3 2025, with a 5-year trough of 1452.36% in Q4 2021.
  • For the 5-year period, Mirum Pharmaceuticals' EBITDA Margin averaged around 208.53%, with its median value being 58.71% (2023).
  • Per our database at Business Quant, Mirum Pharmaceuticals' EBITDA Margin surged by 13299400bps in 2022 and then surged by 159900bps in 2025.
  • Quarter analysis of 5 years shows Mirum Pharmaceuticals' EBITDA Margin stood at 1452.36% in 2021, then surged by 92bps to 122.41% in 2022, then skyrocketed by 62bps to 46.85% in 2023, then surged by 48bps to 24.36% in 2024, then surged by 108bps to 1.96% in 2025.
  • Its last three reported values are 1.96% in Q3 2025, 3.9% for Q2 2025, and 13.61% during Q1 2025.